Kornimate/medical-research-clean huggingface dataset:
ventilatory management of the preterm neonate in the delivery room

Conditions: Respiratory Distress Syndrome, Newborn

Summary: the purpose of this study is to evaluate sustained lung inflation followed by early ncpap as delivery room ventilatory management for preterm neonates at risk of respiratory distress syndrome in reducing their need for mechanical ventilation and ameliorating lung injury without inducing adverse effects compared with intermittent bag and mask ventilation.

neonatal resuscitation provides lifesaving intervention that, if properly conducted, not only can reduce mortality but probably can significantly decrease subsequent morbidity. premature infants need appropriate respiratory support and a lung-protective strategy, starting from the delivery room where, on the contrary, an inadequate respiratory approach may influence pulmonary outcome. mechanical ventilation in the form of positive pressure ventilation has remained the mainstay of treatment of respiratory distress syndrome (rds) in preterm babies. in recent years, a number of new ventilation strategies have been introduced but the problem of bronchopulmonary dysplasia (bpd) has not been solved. sustained lung inflation (sli) lead to a large increase in the tidal volume and the functional residual capacity(fcr) as this intervention may influence the clearance of lung fluids and allow a more even distribution of air throughout the lungs, thus facilitating the formation of frc. nasal cpap and early peep act through stabilization and subsequent recruitment of collapsed alveoli, increased frc resulting in increased alveolar surface area for gas exchange and a decrease in intrapulmonary shunt .also it conserves endogenous surfactant. previous studies with promising results showed that a combination of sustained lung inflation and early nasal cpap may be the most effective and least injurious way to recruit the lung in preterm neonates at birth. this study will evaluate sustained lung inflation followed by early ncpap as delivery room ventilatory management for preterm neonates at risk of respiratory distress syndrome in reducing their need for mechanical ventilation and ameliorating lung injury without inducing adverse effects compared with intermittent bag and mask ventilation.

Eligibility criteria:
inclusion criteria: * preterm infants (gestational age \< 34 weeks) exclusion criteria: * 1. neonates with major congenital anomalies (congenital heart disease, neural tube defect, trisomy, etc.). 2.meconium aspiration syndrome, congenital diaphragmatic hernia and anterior abdominal wall defect. 3.maternal chorioamnionitis. 4.neonates with gestational age \< 26 weeks and /or birth weight less than 750 grams.

Keywords: preterm neonates delivery room resuscitation ventilation neopuff cpap
chronic administration of diosmectite (smecta®) in subjects with chronic diarrhoea

Conditions: Chronic Functional Diarrhea of Unknown Origin

Summary: the main purpose of this study is to assess the concentration of elemental impurities in blood and urine after chronic administration of smecta® in subjects with chronic functional diarrhoea. for exploratory purposes, the potential effects of diosmectite on bowel microbiote composition will be investigated.


Eligibility criteria:
inclusion criteria: * male or female subjects, between 18 and 60 years old inclusive, bmi between 19 and 32 kg/m2 inclusive (minimum body weight of 50 kg at screening). * functional chronic diarrhoea defined as loose or watery stools occurring in at least 75% of stools for the last 3 months (with symptom onset at least 6 months before diagnosis). exclusion criteria: * no history of suspected organic or drug induced cause to chronic diarrhoea.
investigation of the effect of "instrument-assisted soft tissue mobilization" in individuals with lumbar disc herniation

Conditions: Instrument-assisted Soft Tissue Mobilization; Treatment; Exercise; Pain

Summary: instrument-assisted soft tissue mobilization is an instrument-assisted soft tissue mobilization technique. it consists of stainless steel instrument designed to adapt to various tissues/shapes/curves of the body. the instruments were developed as an alternative to transverse friction massage. stainless steel acts a bit like a diaposon when it comes into contact with fibrotic tissue. a resonance or reverberation in the instrument is created upon contact and transmitted through the instrument to the hands of the clinician. the application of heavy pressure (compared to light or medium pressure) using instruments has been proven to promote a greater fibroblastic response. instrument-assisted soft tissue mobilization is not used without insulation. it is imperative to use movement and strengthening in combination with soft tissue mobilization to promote tissue adaptation and remodeling. mechanical loading has been shown to affect chondrocyte alignment and fibroblast activity with increased proteoglycan and collagen synthesis. the aim of this study was to investigate the effects of the iastm technique on individuals of different ages diagnosed with ldh.


Eligibility criteria:
inclusion criteria: 1. individuals have been diagnosed with ldh, 2. their pain is 3 and above according to the visual analog scale (vas), 3. they are between the ages of 20-60, 4. their clinical status is stable, 5. they are fully cooperative, 6. they do not have cognitive, cognitive and mental problems and they can express themselves, 7. they voluntarily agree to participate in the study. exclusion criteria: 1. individuals have psychological disorders, mental disorders, cancer and severe depression, 2. primary or metastatic spinal malignancy, 3. have been diagnosed with advanced osteoporosis, 4. have recently undergone surgical intervention or acute infection, 5. cannot or do not want to perform tests or treatment exercises, 6. want to leave voluntarily.
silicone tube for the surgical treatment of glaucoma

Conditions: Glaucoma, Open-Angle

Summary: the biocompatible silicone tube miniature drainage device is a small, non-valved implant to shunt aqueous humor underneath the conjunctiva to control the intraocular pressure. efficacy and safety were evaluated with a minimum follow-up of 12 months.

patients were examined postoperatively at 1 day, 1 week, 1, 3, 6, 12, 18, 24 months or more frequent when required. iop, bcva and slit lamp biomicroscopy were observed at every visit. history of all medication details and postoperative complications were recorded. one-way analysis of variance (anova) with repeated measures was used to analyze the other differences over time in iop and bcva. nonparametric k-related samples test was used to analyze the difference of medications number at different time points. success rates were evaluated using kaplan-meyer survival analysis curves.

Eligibility criteria:
inclusion criteria:eligible patients were at least 18 years of age and presented with medically uncontrolled poag requiring incisional surgery for iop (intraocular pressure) reduction. - exclusion criteria:exclusion criteria included narrow angles, normal tension glaucoma, previous eye surgery (except cataract surgery), neovascular glaucoma, uveitis, any ocular abnormality that would preclude accurate iop assessment, and inability to comply with the follow-up program or unwillingness to participate in this study. -

Keywords: silicone tube miniature drainage device poag iop
a novel approach to infantile spasms

Conditions: Infantile Spasm

Summary: this study proposes to assess the efficacy of cosyntropin injectable suspension, 1 mg/ml compared to vigabatrin. additionally, this study proposes to determine efficacy of combination therapy of cosyntropin injectable suspension, 1 mg/ml and vigabatrin to monotherapy cosyntropin injectable suspension, 1mg/ml in children with new onset infantile spasms (is).

this is a prospective randomized trial comparing 3 treatment arms: 1. cosyntropin injectable suspension, 1 mg/ml 2. vigabatrin 3. combination of both these therapies, cosyntropin injectable suspension, 1 mg/ml and vigabatrin for treatment of new onset infantile spasms. outcome measures include resolution of clinical spasms, improvement of hypsarrhythmia as well as longer term outcomes of development and subsequent seizures. the data is expected to demonstrate greater efficacy with cosyntropin injectable suspension, 1 mg/ml than vigabatrin for the treatment of is.

Eligibility criteria:
inclusion criteria: * new onset infantile spasms * age \> 2 months * age\< 2 years * hypsarrhythmia on video-eeg * normal renal function exclusion criteria: * prior treatment given for infantile spasms * diagnosis of ohtahara syndrome or early myoclonic epilepsy * absence of hypsarrhythmia * inability for the parent or caregiver to provide consent * inability for the parent or caregiver to complete seizure diary * diagnosis of: * scleroderma, * osteoporosis, * recent systemic fungal infections, * ocular herpes simplex, * recent surgery, * history of or the presence of a peptic ulcer, * congestive heart failure, * uncontrolled hypertension

Keywords: vigabatrin cosyntropin
cerebral palsy early mobility training

Conditions: Cerebral Palsy

Summary: the purpose of this study is to determine the optimal treatment duration of a novel early mobility training program (dynamic supported mobility, dsm) between 6 to 24 weeks of treatment; and to evaluate the clinical futility of this intervention compared to current rehabilitation practice.

this study is a single-blind, randomized exploratory clinical trial with repeated assessments during a 24-week treatment phase and at three follow-up points over 12 months after treatment to track the developmental trajectory of participants' motor function. gross motor ability will be compared to published percentile scores of motor function development in cerebral palsy (cp) to determine if the trajectory of predicted motor development is altered, and to outcomes of intensity-matched conventional treatment to determine if continued phase iii investigation is warranted.

Eligibility criteria:
inclusion criteria: * 12-36 months of age * gross motor function below the 10th percentile for age \[bayley scales of infant and toddler development (bsid), bsid-iii, corrected for gestational age, if applicable, under the age of two years\]. * diagnosis of cp or neurological sign associated with cp (i.e. spasticity). * ability to initiate pulling to stand at a surface \[score of 1 on gross motor function measure (gmfm) item 52\]. * cognitive ability to follow one-step commands. exclusion criteria: * secondary orthopedic, neuromuscular or cardiovascular condition unrelated to cp. * general muscle hypotonia, without other neurological signs associated with cp. * independent walking ability (score of 3 on gmfm item 69 - walks forward 10 steps). * at or above the 50th percentile of gmfcs level i. * history of surgery or injury to the lower extremities in the past 6 months.

Keywords: delay in motor skill development
relationship of different electrocardiographic parameters and ambulatory blood pressure parameters to detect left ventricular hypertrophy

Conditions: Hypertension

Summary: to review the accuracy of electrocardiography in screening for left ventricular hypertrophy in patients with hypertension.

arterial hypertension is a major cause of coronary heart disease, stroke, and heart failure. several studies have shown that left ventricular hypertrophy is an important risk factor in patients with hypertension, leading to a fivefold to 10-fold increase in cardiovascular risk,1 2 3 4 5 which is similar to the increase seen in patients with a history of myocardial infarction.6 the presence of left ventricular hypertrophy, in addition to hypertension, thus has important implications for assessing risk and managing patients, including decisions on interventions other than antihypertensive treatment, such as lipid lowering treatment and lifestyle modifications.7 8 accurate and early diagnosis of left ventricular hypertrophy is therefore an important component of the care of patients with hypertension. decisions about treatment should be based on assessments of hypertensive target organ damage and overall cardiovascular risk. the appropriate diagnostic work-up of suspected left ventricular hypertrophy in patients with hypertension is less clear, however. there is many electrocardiographic indexes for the diagnosis of left ventricular hypertrophy, based on the standard 12 lead electrocardiogram, have been described. many of the proposed indexes have remained anecdotal, but others are commonly used, including the sokolow-lyon index,9 the cornell voltage index,10 the cornell product index,11 the gubner index,12 and the romhilt-estes scores.13 however, debate about their comparative diagnostic value continues.14 15 we did a systematic review to clarify the accuracy of different electrocardiographic indexes, with emphasis on their ability to rule out left ventricular hypertrophy in patients with arterial hypertension.

Eligibility criteria:
inclusion criteria: patients ranging from 20t o 80 years attending the hypertension outpatient clinic for ambulatory blood pressure measurement will be consecutively enrolled exclusion criteria: 1. patients with ischemic heart disease. 2. patients with advanced respiratory, renal, or hepatic disease 3. patients with uninterpretable ecg or abpm recordings
a phase 3 study of telaprevir in combination with pegasys® and copegus® in treatment-naive subjects with genotype 1 hepatitis c virus (hcv)

Conditions: Hepatitis C

Summary: a phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (peg-ifn-alfa-2a) and ribavirin (rbv).


Eligibility criteria:
inclusion criteria * has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis c * male and female subjects, 18 to 70 years of age, inclusive * genotype 1, chronic hepatitis c with detectable hepatitis c virus (hcv) ribonucleic acid (rna) * screening laboratory values, tests, and physical exam within acceptable ranges * able and willing to follow contraception requirements * able to read and understand, and willing to sign the informed consent form and abide by the study restrictions exclusion criteria * subject has any contraindications to pegasys® or copegus® therapy * evidence of hepatic decompensation in cirrhotic subjects * history of organ transplant * history of, or any current medical condition which could impact the safety of the subject in participation in the study

Keywords: genotype 1
ag-013736 in combination with gemcitabine versus gemcitabine alone for patients with metastatic pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: this is a phase 2 study being conducted at multiple centers in the united states, europe and canada. patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. patients must have not had any prior systemic treatment for advanced disease. the purpose of the study is to test whether the angiogenesis inhibitor axitinib \[ag-013736\] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.


Eligibility criteria:
inclusion criteria: * patients with advanced (localized but surgically unresectable or metastatic) histologically/cytologically proven epithelial cancer of the exocrine pancreas * no prior therapy for metastatic disease exclusion criteria: * patients with locally advanced disease who are candidates for radiation therapy. * uncontrolled brain metastases (a controlled brain metastasis must be previously treated, asymptomatic, and without growth for 4 months)

Keywords: randomized phase 2 study of ag-013736 in combination with gemcitabine versus gemcitabine alone in advanced pancreatic cancer
patients navigator for organized colorectal cancer screening

Conditions: Healthy

Summary: the main objective is to evaluate the impact of the recruitment and training of a peer-navigator on the participation rate of colorectal cancer screening among underserved area. the role of the navigator is to establish an intervention culturally-tailored to the inhabitants in order to promote the fecal occult blood test (fobt) and accompany the inhabitants to complementary exams, if needed.


Eligibility criteria:
inclusion criteria: * person living in the iris intervention zones * person invited by the local management structure to participate in colorectal cancer screening exclusion criteria: * person not living in the iris intervention zone * person not invited by the local management structure to participate to colorectal cancer screening
do angiotensin receptor blockers mitigate progression to acute respiratory distress syndrome with sars-cov-2 infection

Conditions: SARS-CoV Infection

Summary: the purpose of this research is to identify whether or not angiotensin receptor blockers (arb) can halt the progression to respiratory failure requiring transfer into the intensive care unit (icu), as well as halt mechanical ventilation in subjects with mild to moderate hypoxia due to the corona virus that causes covid-19. based on previous animal studies, the researchers hypothesize that the addition of an arb is beneficial in abating acute lung injury in subjects in early stages of sars-cov-2 viral induced hypoxia.

this is an investigator initiated, open label, multicenter, two arm, randomized study to compare the impact of adding an arb to the standard of care (soc) to the soc without an arb. randomization ratio will be 1:1. the goal of this study is to identify whether or not arbs have an impact on inhibiting the progression to respiratory failure requiring mechanical ventilation in patients with mild to moderate hypoxia in the setting of covid-19. the addition of an arb to the standard of care treatment for these patients may be beneficial in abating acute lung injury in patients in early stages of sars-cov-2 induced hypoxia.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 positive test result * mild to moderate respiratory symptoms of covid-19. * systolic blood pressure ≥ 105 mmhg. * screen within 3 days of a positive covid-19 test. * age ≥18 years old. * access to a phone in the hospital room or an electronic device that is capable of receiving phone or video calls. * able to read/write/speak english or spanish fluently. * subjects must have the capacity to provide consent or an appropriate lar to provide informed consent. * negative pregnancy test for women of childbearing potential and subject is randomized to the study arm. exclusion criteria: * severe allergy to any arb or ace-inhibitor, including angioedema * in the intensive care unit at screening. * home meds include any kind of ace inhibitor or arb * acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) * hyperkalemia \>5.0 mmol/l at baseline or any time during treatment in the study treatment arm * creatinine clearance \< 30 ml/min at baseline or any time during treatment in the study treatment arm

Keywords: coronavirus angiotensin receptor blocker sars-cov-2 covid-19
bevacizumab with hormonal and radiotherapy for high-risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).

although there is no data on the toxicity with concurrent bevacizumab and hormonal therapy, the combination is not expected to increase toxicity seen when given as a single agent. abnormal tumor microenvironments, tumor progression, and metastatic spread are major factors contributing to treatment failures in radiotherapy. anti-vegf agents (e.g. bevacizumab) can help overcome these factors through several different mechanisims. studies also demonstrate prolonged use of anti-vegf agents with radiation therapy was more effective at preventing metastases from irradiated tumors compared to a short course. patients generally start hormonal therapy and daily radiotherapy at the same time. this study will delay the start of radiotherapy until 8 weeks after the start of hormonal therapy and bevacizumab.

Eligibility criteria:
inclusion criteria: * high risk prostate cancer as defined as one of the following: 1. clinical t2b-t4 2. gleason sum score 8-10 3. psa more than 20 and gleason sum score 7 4. in addition, clinical t2a patients are eligible if 5 or more biopsies contain gleason 4+3 cancer (minimum of 10 biopsies total required) * no evidence of metastatic disease within 60 days of enrollment, confirmed by physical examination, chest x-ray, bone scan, and computed tomography of the abdomen and pelvis * ecog performance status of 0, 1 or 2 exclusion criteria: * concurrent or prior treatment with radiation, cytotoxic, biologic therapy for prostate cancer; any major surgery within four weeks, prior hormonal therapy (except finasteride for obstructive voiding symptoms) * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to day 0 * presence of central nervous system or brain metastases * blood pressure of \>150/100 mmhg * history of myocardial infarction within 6 months * history of stroke within 6 months * current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a genentech-sponsored bevacizumab cancer study

Keywords: prostate cancer high-risk prostate cancer 1st line therapy